Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenobamate in adults with intellectual disability and focal epilepsy
NL-OMON61257Not yet recruiting
- Sponsor
- Angelini Pharma
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of cenobamate in Focal Onset Epilepsy and multifocal epilepsy (2 cohorts), sponsored by Angelini Pharma. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
cenobamate
03
Conditions
Focal Onset Epilepsymultifocal epilepsy
Beyond the preview
Go deeper on NL-OMON61257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61257.